Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
506.50    1.50 (0.30%)
Bid:
506.50
Ask:
507.00
Spread: 0.50 (0.099%)
Market Cap: £2.24b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Trading Statement

8 Feb 2018 07:00

8 February 2018 – Tate & Lyle PLC

TRADING STATEMENT

Tate & Lyle issues the following trading statement for the three months ended 31 December 2017.

The Group saw volume momentum in its Speciality Food Ingredients and Bulk Ingredients divisions and remains on track to deliver progress in adjusted profit before tax in constant currency for the year ending 31 March 2018, in line with guidance.

In Speciality Food Ingredients, the core business delivered good volume growth, including a continuation of modest volume growth in North America. In Food Systems, profit improved although volume was lower. SPLENDA ® Sucralose performed as anticipated with profit in line with the comparative period. In the division overall, decisions taken in the first half, particularly to invest behind the longer term development of the business, will moderate profit growth in the second half.

In Bulk Ingredients, sweetener volume in North America grew and profit growth is currently expected to be robust for the financial year ending 31 March 2018. The 2018 calendar year bulk sweetener pricing round is now substantially complete with margins broadly in line with the previous year.

END

A conference call will be held today at 08.00am GMT, hosted by Javed Ahmed, Chief Executive and Nick Hampton, Chief Executive designate and Chief Financial Officer. Participants are requested to dial in at least 10 minutes before the commencement of the call. Dial in details are as follows:

Standard International Access: +44 (0) 20 3003 2666

Password: Tate & Lyle

A replay of this call will be available after the end of the live call for 14 days until 22 February 2018.

UK replay number: 0208 196 1998

Replay access PIN: 6346734

For more information contact Tate & Lyle PLC:

Christopher Marsh, Group VP, Investor and Media Relations

Tel: +44 (0) 20 7257 2110 or Mobile: +44 (0) 7796 192 688

Andrew Lorenz (FTI Consulting), Media Relations

Tel: +44 (0) 203 727 1323 or Mobile: +44 (0) 7775 641 807

About Tate & Lyle:

Tate & Lyle is a global provider of ingredients and solutions to the food, beverage and other industries, with operations at more than 30 facilities worldwide.

Tate & Lyle operates through two global divisions, Speciality Food Ingredients and Bulk Ingredients, supported by our Innovation and Commercial Development and Global Operations groups. The Group's strategy is to become a leading global provider of Speciality Food Ingredients through a disciplined focus on growth, and by driving Bulk Ingredients for sustained cash generation to fuel this growth.

Speciality Food Ingredients consists of three platforms: Texturants, which includes speciality starches and stabilisers; Sweeteners, which comprises nutritive sweeteners and our range of no-calorie sweeteners including SPLENDA ® Sucralose; and our Health and Wellness portfolio which includes speciality fibres and our salt-reduction offering. Additionally, our Food Systems business provides a wide variety of blended ingredient solutions.

Tate & Lyle Bulk Ingredients includes bulk sweeteners, industrial starches and fermentation products (primarily acidulants). Corn co-products from both divisions are primarily sold as animal feed.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2017, Tate & Lyle sales totalled £2.8 billion. For more information, please visit http://www.tateandlyle.com .

SPLENDA ® is a trademark of Heartland Consumer Products LLC.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180207005974/en/

Copyright Business Wire 2018

Date   Source Headline
9th Dec 20245:25 pmRNSTransaction in Own Shares
6th Dec 20245:33 pmRNSTransaction in Own Shares
5th Dec 20245:38 pmRNSTransaction in Own Shares
5th Dec 20242:30 pmRNSHolding(s) in Company
5th Dec 20242:00 pmRNSDirector/PDMR Shareholding
4th Dec 20245:32 pmRNSTransaction in Own Shares
4th Dec 20244:00 pmRNSHolding(s) in Company
3rd Dec 20245:21 pmRNSTransaction in Own Shares
3rd Dec 20243:00 pmRNSHolding(s) in Company
2nd Dec 20245:31 pmRNSTransaction in Own Shares
2nd Dec 202412:30 pmRNSTotal Voting Rights
29th Nov 20245:41 pmRNSTransaction in Own Shares
28th Nov 20245:21 pmRNSTransaction in Own Shares
27th Nov 20245:31 pmRNSTransaction in Own Shares
26th Nov 20245:48 pmRNSTransaction in Own Shares
26th Nov 20242:30 pmRNSHolding(s) in Company
25th Nov 20245:09 pmRNSTransaction in Own Shares
22nd Nov 20245:28 pmRNSTransaction in Own Shares
21st Nov 20245:24 pmRNSTransaction in Own Shares
20th Nov 20245:44 pmRNSTransaction in Own Shares
20th Nov 20244:30 pmRNSHolding(s) in Company
19th Nov 20245:33 pmRNSTransaction in Own Shares
19th Nov 20243:15 pmRNSHolding(s) in Company
19th Nov 20243:00 pmRNSHolding(s) in Company
18th Nov 20245:20 pmRNSTransaction in Own Shares
18th Nov 20244:00 pmRNSHolding(s) in Company
18th Nov 20248:30 amRNSDirector/PDMR Shareholding
18th Nov 20248:00 amRNSAdmission of New Tate & Lyle Shares
15th Nov 20245:30 pmRNSTransaction in Own Shares
15th Nov 20243:13 pmRNSCompletion of Combination Tate & Lyle and CP Kelco
14th Nov 20245:48 pmRNSTransaction in Own Shares
13th Nov 20245:16 pmRNSTransaction in Own Shares
12th Nov 20245:45 pmRNSTransaction in Own Shares
11th Nov 20245:37 pmRNSTransaction in Own Shares
8th Nov 20245:29 pmRNSTransaction in Own Shares
7th Nov 20245:31 pmRNSTransaction in Own Shares
7th Nov 20247:00 amRNSHalf-year Report
6th Nov 20245:44 pmRNSTransaction in Own Shares
5th Nov 20245:20 pmRNSTransaction in Own Shares
5th Nov 20241:00 pmRNSHolding(s) in Company
4th Nov 20245:28 pmRNSTransaction in Own Shares
1st Nov 20245:44 pmRNSTransaction in Own Shares
1st Nov 202412:15 pmRNSTotal Voting Rights
31st Oct 20245:28 pmRNSTransaction in Own Shares
30th Oct 20245:33 pmRNSTransaction in Own Shares
29th Oct 20245:27 pmRNSTransaction in Own Shares
28th Oct 20245:40 pmRNSTransaction in Own Shares
28th Oct 20244:30 pmRNSHolding(s) in Company
25th Oct 20245:25 pmRNSTransaction in Own Shares
24th Oct 20245:31 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.